Navigation Links
Isis Pharmaceuticals to Present at the UBS Global Life Sciences Conference
Date:9/14/2010

CARLSBAD, Calif., Sept. 14 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at UBS' Global Life Sciences Conference on Tuesday, September 21, 2010 at 4:00 p.m. ET at the Grand Hyatt New York.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 23 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
2. Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference
3. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
4. Transcept Pharmaceuticals to Present at UBS Global Life Sciences Conference
5. Meditrina Pharmaceuticals, Inc. Announces Allowance of Patent for Treatment of Endometriosis
6. Trubion Pharmaceuticals Announces Early Termination of HSR Waiting Period
7. Lotus Pharmaceuticals Announces Engagement of RedChip Companies to Lead Public and Investor Relations Efforts
8. Access Pharmaceuticals to Present At Rodman & Renshaw Annual Global Investment Conference in New York City
9. MAP Pharmaceuticals Reports No Difference in Pulmonary Artery Pressure Between LEVADEX™ and Placebo in Pharmacodynamics Trial
10. Isis Pharmaceuticals to Present at the Stifel Nicolaus 2010 Healthcare Conference
11. MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment in Open-Label Trial and Completion of Treatment in QT Trial for LEVADEX™ Clinical Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/23/2016)... ... June 23, 2016 , ... Representatives of CHA Fertility Centers ... member of their staff, Dr. Joshua J. Berger. As of May 2016, Dr. ... world-renowned facility. , Dr. Berger has received recognition for his research, his teaching and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Horizon Blue Cross Blue Shield ... relief from the crushing burden of sky-high health care costs, Superior Court of ... ruling ( http://www.judiciary.state.nj.us/opinions/a2913-15a2929-15.pdf ) the court provided some analysis of the contracts ...
(Date:6/23/2016)... ... ... As part of an ongoing commitment to encourage living a healthy and ... BCBSNJ) have teamed up with New Jersey native and PGA Tour member Morgan Hoffmann ... lifestyle. , Through Healthy Steps NJ, Hoffmann will share a series of health education ...
(Date:6/23/2016)... ... ... A key metric of this success is the popularity of the Leafedin.org service ... areas that lack the kind of technology and networking framework that LeafedIn.org provide, where ... the marijuana industry, no matter how small or large, and more importantly no matter ...
(Date:6/23/2016)... ... June 23, 2016 , ... King Kullen’s Shop OnLine, the ... to yet another location: Garden City Park. This is the fourth store to be ... grocery delivery service is offered by King Kullen and allows customers to place orders ...
Breaking Medicine News(10 mins):